Article ; Online: A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines.
2024 Volume 48, Issue 3, Page(s) 324–332
Abstract: Background: Botulinum toxin type A is a widely used treatment of facial wrinkles. The objective of this study was to compare the efficacy and safety of a new botulinum toxin type A (Masport [abobotulinum toxin A], MasoonDarou Co) with DYSPORT: Methods! ...
Abstract | Background: Botulinum toxin type A is a widely used treatment of facial wrinkles. The objective of this study was to compare the efficacy and safety of a new botulinum toxin type A (Masport [abobotulinum toxin A], MasoonDarou Co) with DYSPORT Methods: 262 subjects with moderate-to-severe glabellar lines received either a fixed dose of 50 units of MASPORT Results: According to the investigator evaluations, the responder rate at maximum frown were 94.5% for MASPORT and 95.6% for DYSPORT group on day 30 and at rest were 85.45% and 85.68% for MASPORT and DYSPORT group, respectively. According to the subject self-assessment, the proportion of responders in MASPORT group at day 30 was 95.28% versus 97.04% for DYSPORT group. No serious drug related adverse effect was recorded in either study groups, and the rates of adverse effects were similar for both groups. Conclusion: Abobotulinum toxin A [MASPORT] is equally safe and effective as commercial product [DYSPORT] for the treatment of glabellar lines with the dose of 50 units, up to 120 days. Level of evidence i: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 . |
---|---|
MeSH term(s) | Humans ; Botulinum Toxins, Type A/adverse effects ; Treatment Outcome ; Forehead ; Injections, Intramuscular ; Skin Aging ; Drug-Related Side Effects and Adverse Reactions ; Neuromuscular Agents/adverse effects ; Double-Blind Method |
Chemical Substances | abobotulinumtoxinA (EC 3.4.24.69) ; Botulinum Toxins, Type A (EC 3.4.24.69) ; Neuromuscular Agents |
Language | English |
Publishing date | 2024-01-17 |
Publishing country | United States |
Document type | Clinical Trial, Phase III ; Journal Article |
ZDB-ID | 532791-x |
ISSN | 1432-5241 ; 0364-216X |
ISSN (online) | 1432-5241 |
ISSN | 0364-216X |
DOI | 10.1007/s00266-023-03766-5 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1296: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.